Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of V116 versus PPSV23 in at-risk children and adolescents previously vaccinated against pneumococcal disease
MOH_2024-03-11_013031Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of pneumococcal 21-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine, sponsored by Merck & Co. Started Feb 2024; status: active, not recruiting.
02
Drugs
pneumococcal 21-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
Beyond the preview
Go deeper on MOH_2024-03-11_013031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-11_013031.